<H1>Chapter DOI: 10.1208/aapsj070234<br/>Cited-By Count: 35</H1><table border="1" width="30%"><tr><td>Total References</td><td>25</td></tr><tr><td>Springer references</td><td>1</td></tr><tr><td>Non Springer references</td><td>24</td></tr><tr><td>BibStructured Count</td><td width="10%">20</td></tr><tr><td>BibUnstructured Count</td><td width="10%">5</td></tr><tr><td>DOI already available in SpringerLink</td><td>17</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>0</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>0</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>0</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Bigoni R, Giuliani S, Calo' G, et al. Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies.<Emphasis Type="Italic">Naunyn Schmiedebergs Arch Pharmacol.</Emphasis> 1999;359:160&#8211;167.</td><td><a href=http://dx.doi.org/10.1007/PL00005338>10.1007/PL00005338</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibArticle</td><td>Mollereau C, Mouledous L. Tissue distribution of the opioid receptor-like (ORL1) receptor.<Emphasis Type="Italic">Peptides</Emphasis>. 2000;21:907&#8211;917.</td><td><a href=http://dx.doi.org/10.1016/S0196-9781(00)00227-8>10.1016/S0196-9781(00)00227-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3</td><td>BibArticle</td><td>Mogil JS, Pasternak GW. The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family.<Emphasis Type="Italic">Pharmacol Rev.</Emphasis> 2001;53:381&#8211;415.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Calo' G, Guerrini R, Rizzi A, Salvadori S, Regoli D. Pharmacology of noniceptin and its receptor: a novel therapeutic target.<Emphasis Type="Italic">Br J Pharmacol.</Emphasis> 2000;129:1261&#8211;1283.</td><td><a href=http://dx.doi.org/10.1038/sj.bjp.0703219>10.1038/sj.bjp.0703219</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5</td><td>BibArticle</td><td>Zaveri N, Polgar WE, Olsen CM, et al. Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors.<Emphasis Type="Italic">Eur J Pharmacol.</Emphasis> 2001;428:29&#8211;36.</td><td><a href=http://dx.doi.org/10.1016/S0014-2999(01)01282-1>10.1016/S0014-2999(01)01282-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Lutfy K, Eitan S, Bryant C, et al. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors.<Emphasis Type="Italic">J Neurosci.</Emphasis> 2003;23: 10331&#8211;10337.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR7</td><td>BibArticle</td><td>Zaveri N. Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents.<Emphasis Type="Italic">Life Sci.</Emphasis> 2003;73:663&#8211;678.</td><td><a href=http://dx.doi.org/10.1016/S0024-3205(03)00387-4>10.1016/S0024-3205(03)00387-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Ronzoni S, Peretto I, Giardina GA. Lead generation and lead optimization approaches in the discovery of selective, nonpeptide ORL-1 receptor agonists and antagonists.<Emphasis Type="Italic">Expert Opin Ther Patents</Emphasis>. 2001;11:525&#8211;546.</td><td><a href=http://dx.doi.org/10.1517/13543776.11.4.525>10.1517/13543776.11.4.525</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Zaveri NT, Jiang F, Olsen CM, et al. A novel series of piperidin-4-yl-1,3-dihydroindol-2-ones as agonist and antagonist ligands at the nociceptin receptor.<Emphasis Type="Italic">J Med Chem.</Emphasis> 2004;47:2973&#8211;2976.</td><td><a href=http://dx.doi.org/10.1021/jm034249d>10.1021/jm034249d</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10</td><td>BibArticle</td><td>Wichmann J, Adam G, Rover S, et al. Synthesis of (1S,3aS)-8-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one, a potent and selective orphanin FO (OFQ) receptor agonist with anxiolytic-like properties.<Emphasis Type="Italic">Eur J Med Chem.</Emphasis> 2000;35:839&#8211;851.</td><td><a href=http://dx.doi.org/10.1016/S0223-5234(00)00171-9>10.1016/S0223-5234(00)00171-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11</td><td>BibArticle</td><td>Rover S, Adam G, Cesura AM, et al. High-affinity, non-peptide agonists for the ORL1 (orphanin FQ/nociceptin) receptor.<Emphasis Type="Italic">J Med Chem.</Emphasis> 2000;43:1329&#8211;1338.</td><td><a href=http://dx.doi.org/10.1021/jm991129q>10.1021/jm991129q</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Rover S, Wichmann J, Jenck F, Adam G, Cesura AM. ORL1 receptor ligands: structure-activity relationships of 8-cycloalkyl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-ones.<Emphasis Type="Italic">Bioorg Med Chem Lett.</Emphasis> 2000;10:831&#8211;834.</td><td><a href=http://dx.doi.org/10.1016/S0960-894X(00)00111-6>10.1016/S0960-894X(00)00111-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Ito</span> <span style='background:#DDDDDD'>F</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Ohashi</span> <span style='background:#DDDDDD'>Y</span></span></aug>, <span style='background:#FFD9B3'>inventor</span>. <span style='background:#FFFF49'>Pfizer, Inc.</span>, assignee. 1,3,8-Triazaspiro[4,5]decanone compounds as ORL1-receptor agonists. European patent application, European patent 0 997 464 A1. July 10, <span style='background:#66FF66'>1999</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Kolczewski S, Adam G, Cesura AM, et al. Novel hexahydrospiro [piperidine-4,1&#8242;[3,4-c]pyrroles]: highly selective small-molecule nociceptin/orphanin FQ receptors agonists.<Emphasis Type="Italic">J Med Chem.</Emphasis> 2003;46:255&#8211;264.</td><td><a href=http://dx.doi.org/10.1021/jm0209174>10.1021/jm0209174</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Tulshian</span> <span style='background:#DDDDDD'>D</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Ho</span> <span style='background:#DDDDDD'>GD</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Silverman</span> <span style='background:#DDDDDD'>LS</span></span>, et al,</aug> inventor. Schering Corporation, assignee. High affinity ligands for nociceptin receptor ORL-1. US patent 6 262 066 B1. July 17, <span style='background:#66FF66'>2001</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR16</td><td>BibArticle</td><td>Chen Z, Miller WS, Shan S, Valenzano KJ. Design and parallel synthesis of piperidine libraries targeting the nociceptin (N/OFQ) receptor.<Emphasis Type="Italic">Bioorg Med Chem Lett.</Emphasis> 2003;13:3247&#8211;3252.</td><td><a href=http://dx.doi.org/10.1016/S0960-894X(03)00665-6>10.1016/S0960-894X(03)00665-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17</td><td>BibArticle</td><td>Kawamoto H, Ozaki S, Itoh Y, et al. Discovery of the first potent and selective small molecular opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397).<Emphasis Type="Italic">J Med Chem.</Emphasis> 1999;42:5061&#8211;5063.</td><td><a href=http://dx.doi.org/10.1021/jm990517p>10.1021/jm990517p</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18</td><td>BibUnstructured</td><td>Ozaki S, Kawamoto H, Ito Y, Hayashi K, Hirano K, Iwasawa Y, inventor. Banyu Pharmaceutical Co., assignee. New 2-oxoimidazole derivatives. US patent 6 258 825. July 10, 2001.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR19</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Kawamoto</span> <span style='background:#DDDDDD'>H</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Ozaki</span> <span style='background:#DDDDDD'>S</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Ito</span>, <span style='background:#DDDDDD'>Y</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Iwazawa</span> <span style='background:#DDDDDD'>Z</span></span>, <span style='background:#BDBAD6'>inventor. Banyu Pharmaceutical Co, assignee. 4-Oxoimidazolidine-5-spiro-nitrogen-containing heterocyclic compound. Japan patent application 20001169476. June 20,</span></aug> <span style='background:#66FF66'>2000</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR20</td><td>BibArticle</td><td>Zaratin PF, Petrone G, Sbacchi M, et al. Modification of nociceptin and morphine tolerance by the selective ORL-1 antagonist (&#8211;)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111).<Emphasis Type="Italic">J Pharmacol Exp Ther.</Emphasis> 2004;308:454&#8211;461.</td><td><a href=http://dx.doi.org/10.1124/jpet.103.055848>10.1124/jpet.103.055848</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21</td><td>BibArticle</td><td>Shinkai H, Ito T, Iida T, Kitao Y, Yamada H, Uchida I. 4-Aminoquinolines: novel nociceptin antagonists with analgesic activity.<Emphasis Type="Italic">J med Chem.</Emphasis> 2000;43:4667&#8211;4677.</td><td><a href=http://dx.doi.org/10.1021/jm0002073>10.1021/jm0002073</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22</td><td>BibArticle</td><td>Yamada H, Nakamoto H, Suzuki Y, Ito T, Aisaka K. Pharmacological profiles of a novel opioid receptor-likel (ORL1) receptor antagonist, JTC-801.<Emphasis Type="Italic">Br J Pharmacol.</Emphasis> 2002;135:323&#8211;332.</td><td><a href=http://dx.doi.org/10.1038/sj.bjp.0704478>10.1038/sj.bjp.0704478</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Muratani</span> <span style='background:#DDDDDD'>T</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Minami</span> <span style='background:#DDDDDD'>T</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Enomoto</span> <span style='background:#DDDDDD'>U</span></span>, et al.</aug> <span style='background:#CCCCFF'>Characterization of nociceptin/orphanin FQ-induced pain responses by the novel receptor antagonist N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl) benzamide monohydrochloride</span>. <span style='background:#CCFF99'>In:<i>J Pharmacol Exp Ther</i></span>. vol.&amp;nbsp;303. <span style='background:#FFCC66'>2002</span>:<span style='background:#D279FF'>424&#8211;430</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR24</td><td>BibArticle</td><td>Mabuchi T, Matsumura S, Okuda-Ashitaka E, et al. Attenuation of neuropathic pain by the nociceptin/orphanin FQ antagonist JTC-801 is mediated by inhibition of nitric oxide production.<Emphasis Type="Italic">Eur J Neurosci.</Emphasis> 2003;17:1384&#8211;1392.</td><td><a href=http://dx.doi.org/10.1046/j.1460-9568.2003.02575.x>10.1046/j.1460-9568.2003.02575.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25</td><td>BibArticle</td><td>Mouledous L, Topham CM, Moisand C, Mollereau C, Meunier JC. Functional inactivation of the nociceptin receptor by alanine substitution of glutamine 286 at the C terminus of transmembrane segment VI: evidence from a site-directed mutagenesis study of the ORL1 receptor transmembrane-binding domain.<Emphasis Type="Italic">Mol Pharmacol.</Emphasis> 2000,57:495&#8211;502.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></table>